New CEO Appointed From Within Sienna
19-Apr-2017 Sienna Cancer Diagnostics Ltd today announced the Board’s decision to appoint Matthew Hoskin to the position of Chief Executive Officer (CEO). Matthew has served as Chief Operating Officer (COO) for the past 3 years, and will lead the business through its next phase of growth.
Dr Geoffrey Cumming, Sienna’s Chairman said “The Board is extremely pleased with progress the company has made in recent times, and recognises that Matthew’s leadership has been instrumental in driving that progress. The Board is confident that under Matthew’s guidance Sienna will continue to achieve the company’s strategic goals.”
Mr Hoskin added: “The Sienna team has accomplished some key goals over the last six months, including IVD Registration in the US, Europe and Australia to support the commercialisation strategy for our first commercial reagent. In addition, we have appointed distribution partners in the US, UK, and Switzerland, which creates sales and marketing capability to power customer uptake. I'm excited to lead Sienna forward as we expand the market reach of this first product and work to add complementary products to Sienna’s portfolio. I look forward to working closely with the Board to drive the company’s strategic development and growth opportunities.”